{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:57:19Z","timestamp":1777906639913,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00108-021-01223-6","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T14:03:56Z","timestamp":1641218636000},"page":"43-50","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Langzeitmorbidit\u00e4t beim adrenogenitalen Syndrom","Long-term morbidity in congenital adrenal hyperplasia"],"prefix":"10.1007","volume":"63","author":[{"given":"Lea","family":"Tschaidse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friederike","family":"Quitter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Reisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"1223_CR1","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1530\/EJE-14-0824","volume":"172","author":"B Allolio","year":"2015","unstructured":"Allolio\u00a0B (2015) Extensive expertise in endocrinology. Adrenal crisis. Eur J Endocrinol 172:R115\u2013R124","journal-title":"Eur J Endocrinol"},{"key":"1223_CR2","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1210\/jc.2010-0917","volume":"95","author":"W Arlt","year":"2010","unstructured":"Arlt\u00a0W, Willis\u00a0DS, Wild\u00a0SH et\u00a0al (2010) Health status of adults with congenital adrenal hyperplasia: a\u00a0cohort study of 203\u00a0patients. J\u00a0Clin Endocrinol Metab 95:5110\u20135121","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR3","doi-asserted-by":"publisher","first-page":"105734","DOI":"10.1016\/j.jsbmb.2020.105734","volume":"204","author":"MK Auer","year":"2020","unstructured":"Auer\u00a0MK, Paizoni\u00a0L, Hofbauer\u00a0LC et al (2020) Effects of androgen excess and glucocorticoid exposure on bone health in adult patients with 21-hydroxylase deficiency. J\u00a0Steroid Biochem Mol Biol 204:105734","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1223_CR4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MED.0000000000000308","volume":"24","author":"W Bonfig","year":"2017","unstructured":"Bonfig\u00a0W (2017) Growth and development in children with classic congenital adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes 24:39\u201342","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1223_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/ajh\/hpv087","volume":"29","author":"W Bonfig","year":"2016","unstructured":"Bonfig\u00a0W, Roehl\u00a0FW, Riedl\u00a0S et al (2016) Blood pressure in a\u00a0large cohort of children and adolescents with Classic Adrenal Hyperplasia (CAH) due to 21-hydroxylase deficiency. Am J Hypertens 29:266\u2013272","journal-title":"Am J Hypertens"},{"key":"1223_CR6","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1111\/cen.12498","volume":"81","author":"W Bonfig","year":"2014","unstructured":"Bonfig\u00a0W, Schwarz\u00a0HP (2014) Blood pressure, fludrocortisone dose and plasma renin activity in children with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency followed from birth to 4\u00a0years of age. Clin Endocrinol (Oxf) 81:871\u2013875","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1223_CR7","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/j.1365-2265.2009.03563.x","volume":"70","author":"A Casteras","year":"2009","unstructured":"Casteras\u00a0A, De Silva\u00a0P, Rumsby\u00a0G et\u00a0al (2009) Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. Clin Endocrinol (Oxf) 70:833\u2013837","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1223_CR8","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1210\/jc.2006-1311","volume":"92","author":"HL Claahsen-Van Der Grinten","year":"2007","unstructured":"Claahsen-Van Der Grinten\u00a0HL, Otten\u00a0BJ, Takahashi\u00a0S et al (2007) Testicular adrenal rest tumors in adult males with congenital adrenal hyperplasia: evaluation of pituitary-gonadal function before and after successful testis-sparing surgery in eight patients. J\u00a0Clin Endocrinol Metab 92:612\u2013615","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR9","doi-asserted-by":"publisher","first-page":"R85","DOI":"10.1530\/EJE-20-1093","volume":"184","author":"HL Claahsen-Van Der Grinten","year":"2021","unstructured":"Claahsen-Van Der Grinten\u00a0HL, Stikkelbroeck\u00a0N, Falhammar\u00a0H et al (2021) Management of endocrine disease: gonadal dysfunction in congenital adrenal hyperplasia. Eur J Endocrinol 184:R85\u2013R97","journal-title":"Eur J Endocrinol"},{"key":"1223_CR10","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00431-017-3008-7","volume":"176","author":"M Dumic","year":"2017","unstructured":"Dumic\u00a0M, Duspara\u00a0V, Grubic\u00a0Z et al (2017) Testicular adrenal rest tumors in congenital adrenal hyperplasia-cross-sectional study of 51 Croatian male patients. Eur J Pediatr 176:1393\u20131404","journal-title":"Eur J Pediatr"},{"key":"1223_CR11","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1016\/S0140-6736(17)31431-9","volume":"390","author":"D El-Maouche","year":"2017","unstructured":"El-Maouche\u00a0D, Arlt\u00a0W, Merke\u00a0DP (2017) Congenital adrenal hyperplasia. Lancet 390:2194\u20132210","journal-title":"Lancet"},{"key":"1223_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.psyneuen.2015.06.017","volume":"60","author":"H Engberg","year":"2015","unstructured":"Engberg\u00a0H, Butwicka\u00a0A, Nordenstr\u00f6m\u00a0A et\u00a0al (2015) Congenital adrenal hyperplasia and risk for psychiatric disorders in girls and women born between 1915 and 2010: A total population study. Psychoneuroendocrinology 60:195\u2013205","journal-title":"Psychoneuroendocrinology"},{"key":"1223_CR13","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1210\/er.2018-00258","volume":"40","author":"M Engels","year":"2019","unstructured":"Engels\u00a0M, Span\u00a0PN, Van Herwaarden\u00a0AE et\u00a0al (2019) Testicular adrenal rest tumors: current insights on prevalence, characteristics, origin, and treatment. Endocr Rev 40:973\u2013987","journal-title":"Endocr Rev"},{"key":"1223_CR14","doi-asserted-by":"publisher","first-page":"E554","DOI":"10.1210\/jc.2013-3707","volume":"99","author":"H Falhammar","year":"2014","unstructured":"Falhammar\u00a0H, Butwicka\u00a0A, Land\u00e9n\u00a0M et al (2014) Increased psychiatric morbidity in men with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J\u00a0Clin Endocrinol Metab 99:E554\u2013E560","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR15","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1210\/jc.2007-0744","volume":"92","author":"H Falhammar","year":"2007","unstructured":"Falhammar\u00a0H, Filipsson\u00a0H, Holmdahl\u00a0G et al (2007) Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J\u00a0Clin Endocrinol Metab 92:4643\u20134649","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR16","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1210\/JC.2015-2093","volume":"100","author":"H Falhammar","year":"2015","unstructured":"Falhammar\u00a0H, Frisen\u00a0L, Hirschberg\u00a0AL et al (2015) Increased cardiovascular and metabolic morbidity in patients with 21-hydroxylase deficiency: a Swedish population-based national cohort study. J\u00a0Clin Endocrinol Metab 100:3520\u20133528","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR17","doi-asserted-by":"publisher","first-page":"E2715","DOI":"10.1210\/jc.2014-2957","volume":"99","author":"H Falhammar","year":"2014","unstructured":"Falhammar\u00a0H, Fris\u00e9n\u00a0L, Norrby\u00a0C et al (2014) Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J\u00a0Clin Endocrinol Metab 99:E2715\u2013E2721","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR18","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/humrep\/den118","volume":"23","author":"K Hagenfeldt","year":"2008","unstructured":"Hagenfeldt\u00a0K, Janson\u00a0PO, Holmdahl\u00a0G et al (2008) Fertility and pregnancy outcome in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hum Reprod 23:1607\u20131613","journal-title":"Hum Reprod"},{"key":"1223_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1530\/EJE-12-1057","volume":"169","author":"S Hahner","year":"2013","unstructured":"Hahner\u00a0S, Burger-Stritt\u00a0S, Allolio\u00a0B (2013) Subcutaneous hydrocortisone administration for emergency use in adrenal insufficiency. Eur J Endocrinol 169:147\u2013154","journal-title":"Eur J Endocrinol"},{"key":"1223_CR20","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1530\/EJE-09-0884","volume":"162","author":"S Hahner","year":"2010","unstructured":"Hahner\u00a0S, Loeffler\u00a0M, Bleicken\u00a0B et\u00a0al (2010) Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur J Endocrinol 162:597\u2013602","journal-title":"Eur J Endocrinol"},{"key":"1223_CR21","doi-asserted-by":"publisher","first-page":"e957","DOI":"10.1210\/clinem\/dgaa801","volume":"106","author":"AL Hirschberg","year":"2021","unstructured":"Hirschberg\u00a0AL, Gidl\u00f6f\u00a0S, Falhammar\u00a0H et al (2021) Reproductive and perinatal outcomes in women with congenital adrenal hyperplasia: a population-based cohort study. J\u00a0Clin Endocrinol Metab 106:e957\u2013e965","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR22","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/s41431-021-00870-5","volume":"29","author":"Q Lao","year":"2021","unstructured":"Lao\u00a0Q, Merke\u00a0DP (2021) Molecular genetic testing of congenital adrenal hyperplasia due to 21-hydroxylase deficiency should include CAH\u2011X chimeras. Eur J Hum Genet 29:1047\u20131048","journal-title":"Eur J Hum Genet"},{"key":"1223_CR23","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1056\/NEJMra1909786","volume":"383","author":"DP Merke","year":"2020","unstructured":"Merke\u00a0DP, Auchus\u00a0RJ (2020) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N\u00a0Engl J Med 383:1248\u20131261","journal-title":"N Engl J Med"},{"key":"1223_CR24","doi-asserted-by":"publisher","first-page":"e2063","DOI":"10.1210\/clinem\/dgab051","volume":"106","author":"DP Merke","year":"2021","unstructured":"Merke\u00a0DP, Mallappa\u00a0A, Arlt\u00a0W et al (2021) Modified-release hydrocortisone in congenital adrenal hyperplasia. J\u00a0Clin Endocrinol Metab 106:e2063\u2013e2077","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s10508-017-1003-8","volume":"47","author":"HF Meyer-Bahlburg","year":"2018","unstructured":"Meyer-Bahlburg\u00a0HF, Khuri\u00a0J, Reyes-Portillo\u00a0J et al (2018) Stigma associated with classical congenital adrenal hyperplasia in women\u2019s sexual lives. Arch Sex Behav 47:943\u2013951","journal-title":"Arch Sex Behav"},{"key":"1223_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000481911","volume":"89","author":"WL Miller","year":"2018","unstructured":"Miller\u00a0WL, Merke\u00a0DP (2018) Tenascin\u2011X, congenital adrenal hyperplasia, and the CAH\u2011X syndrome. Horm Res Paediatr 89:352\u2013361","journal-title":"Horm Res Paediatr"},{"key":"1223_CR27","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1210\/jc.2009-2616","volume":"95","author":"K Muthusamy","year":"2010","unstructured":"Muthusamy\u00a0K, Elamin\u00a0MB, Smushkin\u00a0G et\u00a0al (2010) Clinical review: adult height in patients with congenital adrenal hyperplasia: a\u00a0systematic review and metaanalysis. J\u00a0Clin Endocrinol Metab 95:4161\u20134172","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR28","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1210\/jc.2007-0556","volume":"93","author":"A Nordenskjold","year":"2008","unstructured":"Nordenskjold\u00a0A, Holmdahl\u00a0G, Frisen\u00a0L et al (2008) Type of mutation and surgical procedure affect long-term quality of life for women with congenital adrenal hyperplasia. J\u00a0Clin Endocrinol Metab 93:380\u2013386","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR29","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1210\/jc.2009-2639","volume":"95","author":"A Nordenstrom","year":"2010","unstructured":"Nordenstrom\u00a0A, Frisen\u00a0L, Falhammar\u00a0H et\u00a0al (2010) Sexual function and surgical outcome in women with congenital adrenal hyperplasia due to CYP21A2 deficiency: clinical perspective and the patients\u2019 perception. J\u00a0Clin Endocrinol Metab 95:3633\u20133640","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR30","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1530\/EJE-14-1114","volume":"172","author":"M Quinkler","year":"2015","unstructured":"Quinkler\u00a0M, Miodini Nilsen\u00a0R, Zopf\u00a0K et al (2015) Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur J Endocrinol 172:619\u2013626","journal-title":"Eur J Endocrinol"},{"key":"1223_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12955-018-0881-3","volume":"16","author":"M Rapp","year":"2018","unstructured":"Rapp\u00a0M, Mueller-Godeffroy\u00a0E, Lee\u00a0P et al (2018) Multicentre cross-sectional clinical evaluation study about quality of life in adults with disorders\/differences of sex development (DSD) compared to country specific reference populations (dsd-LIFE). Health Qual Life Outcomes 16:54","journal-title":"Health Qual Life Outcomes"},{"key":"1223_CR32","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1055\/a-0820-2085","volume":"127","author":"N Reisch","year":"2019","unstructured":"Reisch\u00a0N (2019) Review of health problems in adult patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Exp Clin Endocrinol Diabetes 127:171\u2013177","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1223_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1530\/EJE-12-0161","volume":"167","author":"N Reisch","year":"2012","unstructured":"Reisch\u00a0N, Willige\u00a0M, Kohn\u00a0D et al (2012) Frequency and causes of adrenal crises over lifetime in patients with 21-hydroxylase deficiency. Eur J Endocrinol 167:35\u201342","journal-title":"Eur J Endocrinol"},{"key":"1223_CR34","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1210\/jc.2009-2631","volume":"95","author":"PW Speiser","year":"2010","unstructured":"Speiser\u00a0PW, Azziz\u00a0R, Baskin\u00a0LS et al (2010) Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J\u00a0Clin Endocrinol Metab 95:4133\u20134160","journal-title":"J Clin Endocrinol Metab"},{"key":"1223_CR35","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1210\/jc.2018-01862","volume":"103","author":"S Tamhane","year":"2018","unstructured":"Tamhane\u00a0S, Rodriguez-Gutierrez\u00a0R, Iqbal\u00a0AM et al (2018) Cardiovascular and metabolic outcomes in congenital adrenal hyperplasia: a systematic review and meta-analysis. J\u00a0Clin Endocrinol Metab 103:4097\u20134103","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01223-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-01223-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01223-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T06:25:19Z","timestamp":1700029519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-01223-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1223"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-01223-6","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"10 November 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"L.\u00a0Tschaidse, F.\u00a0Quitter und A.\u00a0H\u00fcbner geben an, dass kein Interessenkonflikt besteht. N.\u00a0Reisch war verantwortlich f\u00fcr die Phase-III- und Extension-Studie von Chronocort (Efmody\u00ae) und die EU-AIR-SHP617-400-P40012-Studie, sie ist verantwortlich f\u00fcr die CRH-Rezeptor-Antagonisten-Studien (Phase\u00a0III: Neurocrine Biosciences; Phase\u00a0IIb: Spruce Biosciences) am Standort Medizinische Klinik IV, LMU M\u00fcnchen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autorinnen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}